Literature DB >> 19050274

Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage.

Elodie Belnoue1, Tatiana Voza, Fabio T M Costa, Anne Charlotte Grüner, Marjorie Mauduit, Daniela Santoro Rosa, Nadya Depinay, Michèle Kayibanda, Ana Margarida Vigário, Dominique Mazier, Georges Snounou, Photini Sinnis, Laurent Rénia.   

Abstract

Immunity to malaria has long been thought to be stage-specific. In this study we show that immunization of BALB/c mice with live erythrocytes infected with nonlethal strains of Plasmodium yoelii under curative chloroquine cover conferred protection not only against challenge by blood stage parasites but also against sporozoite challenge. This cross-stage protection was dose-dependent and long lasting. CD4(+) and CD8(+) T cells inhibited malaria liver but not blood stage. Their effect was mediated partially by IFN-gamma, and was completely dependent of NO. Abs against both pre-erythrocytic and blood parasites were elicited and were essential for protection against blood stage and liver stage parasites. Our results suggest that Ags shared by liver and blood stage parasites can be the foundation for a malaria vaccine that would provide effective protection against both pre-erythrocytic and erythrocytic asexual parasites found in the mammalian host.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050274      PMCID: PMC5551044          DOI: 10.4049/jimmunol.181.12.8552

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Interleukin 12 induction of interferon gamma-dependent protection against malaria.

Authors:  M Sedegah; F Finkelman; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

2.  Genetically modified Plasmodium parasites as a protective experimental malaria vaccine.

Authors:  Ann-Kristin Mueller; Mehdi Labaied; Stefan H I Kappe; Kai Matuschewski
Journal:  Nature       Date:  2004-12-05       Impact factor: 49.962

3.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Authors:  Stephen L Hoffman; Lucy M L Goh; Thomas C Luke; Imogene Schneider; Thong P Le; Denise L Doolan; John Sacci; Patricia de la Vega; Megan Dowler; Chris Paul; Daniel M Gordon; Jose A Stoute; L W Preston Church; Martha Sedegah; D Gray Heppner; W Ripley Ballou; Thomas L Richie
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

4.  Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface.

Authors:  Ann-Kristin Mueller; Nelly Camargo; Karine Kaiser; Cathy Andorfer; Ute Frevert; Kai Matuschewski; Stefan H I Kappe
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

5.  Acute malaria prolongs susceptibility of mice to Plasmodium berghei sporozoite infection.

Authors:  A U Orjih
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

6.  A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle.

Authors:  Blandine Franke-Fayard; Holly Trueman; Jai Ramesar; Jacqui Mendoza; Maarten van der Keur; Reinier van der Linden; Robert E Sinden; Andrew P Waters; Chris J Janse
Journal:  Mol Biochem Parasitol       Date:  2004-09       Impact factor: 1.759

7.  In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants.

Authors:  A K Nussler; L Rénia; V Pasquetto; F Miltgen; H Matile; D Mazier
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

8.  TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6.

Authors:  A Nussler; S Pied; J Goma; L Rénia; F Miltgen; G E Grau; D Mazier
Journal:  Int Immunol       Date:  1991-04       Impact factor: 4.823

9.  IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism.

Authors:  S Mellouk; S J Green; C A Nacy; S L Hoffman
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

10.  Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.

Authors:  L Rénia; I T Ling; M Marussig; F Miltgen; A A Holder; D Mazier
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

View more
  49 in total

1.  Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.

Authors:  Xiaohong Peng; Gladys J Keitany; Marissa Vignali; Lin Chen; Claire Gibson; Kimberly Choi; Fusheng Huang; Ruobing Wang
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

2.  Still seeking an effective "one-two" malaria vaccine punch.

Authors:  Joseph D Smith; Brandon K Sack
Journal:  Mol Ther       Date:  2012-12       Impact factor: 11.454

3.  Immunomic Identification of Malaria Antigens Associated With Protection in Mice.

Authors:  Anthony Siau; Ximei Huang; Han Ping Loh; Neng Zhang; Wei Meng; Siu Kwan Sze; Laurent Renia; Peter Preiser
Journal:  Mol Cell Proteomics       Date:  2019-02-04       Impact factor: 5.911

4.  Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites.

Authors:  Noah S Butler; Nathan W Schmidt; Ashley M Vaughan; Ahmed S Aly; Stefan H I Kappe; John T Harty
Journal:  Cell Host Microbe       Date:  2011-06-16       Impact factor: 21.023

Review 5.  Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Authors:  Amber I Raja; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

Review 6.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

Review 8.  Antigens for pre-erythrocytic malaria vaccines: building on success.

Authors:  C Speake; P E Duffy
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

9.  Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10.

Authors:  Prasanna Jagannathan; Katherine Bowen; Felistas Nankya; Tara I McIntyre; Ann Auma; Samuel Wamala; Esther Sikyomu; Kate Naluwu; Mayimuna Nalubega; Michelle J Boyle; Lila A Farrington; Victor Bigira; James Kapisi; Fran Aweeka; Bryan Greenhouse; Moses Kamya; Grant Dorsey; Margaret E Feeney
Journal:  J Infect Dis       Date:  2016-04-10       Impact factor: 5.226

10.  A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites.

Authors:  Marjorie Mauduit; Anne Charlotte Grüner; Rita Tewari; Nadya Depinay; Michèle Kayibanda; Jean-Marc Chavatte; Jean-François Franetich; Andrea Crisanti; Dominique Mazier; Georges Snounou; Laurent Rénia
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.